DEJKA MARIDA ARAUJO to Treatment Outcome
This is a "connection" page, showing publications DEJKA MARIDA ARAUJO has written about Treatment Outcome.
Connection Strength
0.154
-
Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011 Nov 01; 117(21):4939-47.
Score: 0.022
-
Inhibiting the VEGF-VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Curr Opin Oncol. 2010 Jul; 22(4):351-5.
Score: 0.021
-
SABR for Sarcoma Lung Metastases: Indications for Treatment and Guidance for Patient Selection. Int J Radiat Oncol Biol Phys. 2024 Mar 15; 118(4):971-978.
Score: 0.013
-
Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat. 2021 Apr; 186(3):871-882.
Score: 0.011
-
Clinical outcomes of patients with advanced synovial sarcoma or myxoid/round cell liposarcoma treated at major cancer centers in the United States. Cancer Med. 2020 07; 9(13):4593-4602.
Score: 0.010
-
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma. J Immunother Cancer. 2019 10 24; 7(1):276.
Score: 0.010
-
Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol. 2018 12 01; 4(12):e184060.
Score: 0.009
-
Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients. Sci Rep. 2017 08 25; 7(1):9519.
Score: 0.009
-
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med. 2016 12; 5(12):3437-3444.
Score: 0.008
-
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Ann Oncol. 2015 May; 26(5):1012-1018.
Score: 0.007
-
A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: results of a Sarcoma Alliance for Research Through Collaboration study. Cancer. 2014 Aug 15; 120(16):2448-56.
Score: 0.007
-
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. J Hematol Oncol. 2014 Jan 14; 7:8.
Score: 0.007
-
Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med. 2013 Aug; 2(4):553-63.
Score: 0.007
-
Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013 Apr 15; 119(8):1555-61.
Score: 0.006
-
Preoperative radiation therapy in the management of recurrent orbital hemangiopericytoma. Ophthalmic Plast Reconstr Surg. 2011 Sep-Oct; 27(5):e126-8.
Score: 0.006